Anti-vista antibodies and fragments, uses thereof, and methods of identifying same

Patent metadata

Field	Value
Publication number	US-11014987-B2
Application number	US-201715481410-A
Country	US
Kind code	B2
Filing date	Apr 6, 2017
Priority date	Dec 24, 2013
Publication date	May 25, 2021
Grant date	May 25, 2021

Abstract

The present invention relates to antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of eliciting certain biological responses using the antibodies. Compositions and methods of using anti-VISTA antibodies in combination with one or more antibodies that bind to immune checkpoint proteins are also provided.

First claim

What is claimed:

1. A method of enhancing an immune response in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of: a) a first antibody or an antibody fragment thereof comprising an antigen binding region that binds V-domain Ig Suppressor of T cell Activation (VISTA) comprising a VH CDR1 having the amino acid sequence of SEQ ID NO:25, a VH CDR2 having the amino acid sequence of SEQ ID NO:26 and a VH CDR3 having the amino acid sequence of SEQ ID NO:27, and an antibody VL domain comprising a VL CDR1 having the amino acid sequence of SEQ ID NO:28, a VL CDR2 having the amino acid sequence of SEQ ID NO:29 and a VL CDR3 having the amino acid sequence of SEQ ID NO:30; and b) a second antibody or antibody fragment thereof comprising an antigen binding region that binds to PD-1, thereby enhancing an immune response in the individual in need thereof.

2. The method of claim 1 , wherein the second antibody or antibody fragment thereof in b) enhances T cell activation.

3. The method of claim 1 , wherein the first antibody or antibody fragment thereof in a) comprises an antibody VH domain comprising SEQ ID NO:37.

4. The method of claim 1 , wherein the first antibody or antibody fragment thereof in a) comprises an antibody VL domain comprising SEQ ID NO:44.

5. The method of claim 1 , wherein the antibody or antibody fragment thereof in a) comprises an antibody heavy chain comprising SEQ ID NO:61 and an antibody light chain comprising SEQ ID NO:56.

6. The method of claim 1 , wherein the second antibody or antibody fragment thereof in b) is nivolumab or pembrolizumab.

7. The method of claim 1 , wherein the immune response is an antitumor immune response.

8. The method of claim 1 , wherein the immune response is a T cell response.

9. The method of claim 1 , wherein the individual has cancer.

10. The method of claim 9 , wherein the cancer is a solid tumor, a leukemia, a lymphoma, a myelodisplastic syndrome or a myeloma.

11. The method of claim 10 , wherein the solid tumor is a lung tumor, bladder tumor or breast tumor.

12. The method of claim 1 , wherein the first antibody or antibody fragment thereof in a) and the second antibody or antibody fragment thereof in b) are administered simultaneously.

13. The method of claim 1 , wherein the first antibody or antibody fragment thereof in a) and the second antibody or antibody fragment thereof in b) are administered in sequentially.

14. The method of claim 1 , wherein the first antibody or antibody fragment thereof in a) and the second antibody or antibody fragment thereof in b) are administered in the same formulation.

15. The method of claim 1 , wherein the first antibody or antibody fragment thereof in a) and the second antibody or antibody fragment thereof in b) are administered in separate formulations.

16. The method of claim 1 , wherein the first antibody or antibody fragment thereof in a) and the second antibody or antibody fragment thereof in b) are administered intravenously.

Assignees

• Janssen Pharmaceutica Nv
• Janssen Pharmaceutics Nv

Inventors

• Snyder Linda A
• Powers Gordon
• Ubani Enrique Zudaire
• Marvel Douglas Matthew

Classifications

• C07K16/2818

  against CD28 or CD152 · CPC title

• C07K2317/73

  Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K16/2803

  against the immunoglobulin superfamily · CPC title

• A61K2039/507

  Comprising a combination of two or more separate antibodies · CPC title